BioLineRx to Report First Quarter 2018 Results on May 22, 2018
Published: May 16, 2018
TEL AVIV, Israel, May 16, 2018 /PRNewswire/ --BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX)(BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the quarter ended March 31, 2018 on Tuesday, May 22, 2018, before the US markets open.
The Company will host a conference call on Tuesday, May 22, 2018 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations [http://ir.biolinerx.com/phoenix.zhtml?c=208785&p=irol-eventDetails&EventId=5271525 ] page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
To dial into the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations [http://ir.biolinerx.com/phoenix.zhtml?c=208785&p=irol-eventDetails&EventId=5271525 ] page of BioLineRx's website. A dial-in replay of the call will be available until May 25, 2018; please dial +1-877-456-0009 from the U.S. or +972-3-925-5942 internationally.
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and has initiated a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which is expected to initiate a first-in-man study in study in mid-2018. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD (known as Merck in the US and Canada), on the basis of which the Company is carrying out a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA(R); and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications and AML.
For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook [https://www.facebook.com/BioLineRx-786986118113858/?fref=ts ], Twitter [https://twitter.com/BioLineRx_Ltd ], and LinkedIn [https://www.linkedin.com/company/biolinerx ].
Contact: PCG Advisory Vivian Cervantes Investor Relations 646-863-6274 email@example.com or Tsipi Haitovsky Public Relations +972-52-598-9892 firstname.lastname@example.org
SOURCE BioLineRx Ltd.